Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Idiopathic Pulmonary Fibrosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Idiopathic Pulmonary Fibrosis (US)
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. Characterized by the thickening and stiffening of tissues in the lungs, it…
Idiopathic Pulmonary Fibrosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Pirfenidone was the first disease-modifying therapy (DMT) approved for IPF,…
Idiopathic Pulmonary Fibrosis | Treatment Algorithms: Claims Data Analysis | US | 2024
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. Characterized by the thickening and stiffening of tissues in the lungs, it…
Idiopathic Pulmonary Fibrosis – Unmet Need – Unmet Need – Idiopathic Pulmonary Fibrosis (US/EU)
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. IPF…
Idiopathic Pulmonary Fibrosis | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2023
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first disease-modifying therapy (DMT)…
Idiopathic Pulmonary Fibrosis | Treatment Algorithms: Claims Data Analysis | US | 2023
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by the thickening and stiffening of tissues in the lungs…
Idiopathic Pulmonary Fibrosis | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2022
Idiopathic pulmonary fibrosis (IPF), one of the most common interstitial lung diseases, is characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first…
